These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9261531)

  • 1. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
    Judson I; Cerny T; Epelbaum R; Dunlop D; Smyth J; Schaefer B; Roelvink M; Kaplan S; Hanauske A
    Ann Oncol; 1997 Jun; 8(6):604-6. PubMed ID: 9261531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
    Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
    Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
    Fokkema E; Groen HJ; Bauer J; Uges DR; Weil C; Smith IE
    J Clin Oncol; 1999 Dec; 17(12):3822-7. PubMed ID: 10577855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
    Fokkema E; de Vries EG; Meijer S; Groen HJ
    Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.
    George CM; Haraf DJ; Mauer AM; Krauss SA; Hoffman PC; Rudin CM; Szeto L; Vokes EE
    Invest New Drugs; 2001; 19(4):303-10. PubMed ID: 11561689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
    Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer.
    Fukuda M; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Hara K; Saijo N
    Cancer Chemother Pharmacol; 1990; 26(6):393-6. PubMed ID: 2171794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
    McKeage MJ; Mistry P; Ward J; Boxall FE; Loh S; O'Neill C; Ellis P; Kelland LR; Morgan SE; Murrer B
    Cancer Chemother Pharmacol; 1995; 36(6):451-8. PubMed ID: 7554035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
    McKeage MJ; Raynaud F; Ward J; Berry C; O'Dell D; Kelland LR; Murrer B; Santabárabara P; Harrap KR; Judson IR
    J Clin Oncol; 1997 Jul; 15(7):2691-700. PubMed ID: 9215842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of oral JM216 given twice daily.
    Beale P; Raynaud F; Hanwell J; Berry C; Moore S; Odell D; Judson I
    Cancer Chemother Pharmacol; 1998; 42(2):142-8. PubMed ID: 9654114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of carboplatin in non-small cell lung cancer.
    Tamura T; Shinkai T; Eguchi K; Sasaki Y; Fujiwara Y; Fukuda M; Ohe Y; Nakagawa K; Minato K; Saijo N
    Jpn J Clin Oncol; 1989 Mar; 19(1):51-5. PubMed ID: 2537907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase II clinical trial of nedaplatin in advanced non-small cell lung cancer].
    Xu RH; Guan ZZ; Jiang WQ; Huang H; Hu XH; Xie WM; Li XG; Liu YL; Pan LX; Dai AD; Zhuang W; Zhang C; Ma ZY; Wang JH
    Ai Zheng; 2002 Dec; 21(12):1354-8. PubMed ID: 12520747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer].
    Furuse K; Fukuoka M; Kurita Y; Ariyoshi Y; Niitani H; Yoneda S; Fujii M; Hasegawa K; Nishiwaki Y; Tamura M
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):879-84. PubMed ID: 1318698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.
    Gore ME; Calvert AH; Smith LE
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1391-7. PubMed ID: 2824209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on satraplatin: the first orally available platinum anticancer drug.
    Kelland LR
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.
    Schwartsmann G; Schunemann H; Gorini CN; Filho AF; Garbino C; Sabini G; Muse I; DiLeone L; Mans DR
    Invest New Drugs; 2000 Feb; 18(1):83-91. PubMed ID: 10830142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.